Apellis Pharmaceuticals announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter for SYFOVRE for geographic atrophy secondary to age-related macular degeneration and for EMPAVELI for adults with paroxysmal nocturnal hemoglobinuria. “SYFOVRE is the market-leading treatment for GA, with approximately 160,000 doses distributed since launch. More patients than ever are benefiting from SYFOVRE, including the increasing treatment effects over time and flexible dosing, and we look forward to building on the momentum this year,” said Cedric Francois, M.D., Ph.D., co-founder and chief executive officer, Apellis. “Additionally, the high compliance observed with EMPAVELI speaks to the important impact of this medicine on patients’ lives. In addition to advancing our pipeline, we believe the tremendous commercial progress made in the past year has positioned us for an even stronger 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
- Apellis Pharmaceuticals call volume above normal and directionally bullish
- Apellis price target lowered by $3 at Citi, here’s why